Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCV Test and Treat with Simplified Education
NCT05582681Phase 4Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of glecaprevir and pibrentasvir in hepatitis C (HCV), sponsored by Weill Cornell Medicine. Primary endpoint: Number of subjects who initiated treatment within 8-week window from enrollment. Started Nov 2022; status: terminated.
02
Drugs
glecaprevirpibrentasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT05582681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05582681.